Issue Date: July 24, 2006
Gilead will buy Corus Pharma ...
Gilead Sciences intends to exercise its option to acquire Corus Pharma for $365 million. Gilead invested $25 million in Corus in April, becoming the firm's second largest shareholder and gaining the option to buy the rest of the company. Other investors in Corus, which is developing respiratory and infectious disease products, include several investment banks.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society